<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972205</url>
  </required_header>
  <id_info>
    <org_study_id>080035</org_study_id>
    <secondary_id>08-C-0035</secondary_id>
    <nct_id>NCT00972205</nct_id>
    <nct_alias>NCT00658424</nct_alias>
  </id_info>
  <brief_title>Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors</brief_title>
  <official_title>A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1(Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Some cancer cells have a large amount of a protein called P-glycoprotein, which can pump
           certain chemotherapy drugs out of their cells. This pump may be part of the reason why
           it is difficult to shrink some cancers with chemotherapy.

        -  In laboratory experiments, the drug CBT-1(Registered Trademark) blocked the
           P-glycoprotein pump, resulting in accumulation of higher amounts of chemotherapy inside
           the cancer cells, making the chemotherapy more effective.

        -  Paclitaxel is a cancer drug that has caused tumors to shrink in many types of cancers,
           including lung, ovarian, breast, renal, cervical and others.

      Objectives:

        -  To determine whether CBT-1(Registered Trademark) can block the P-glycoprotein pump on
           cancer cells and whether it inhibits the action of the pump found in normal blood cells
           and liver tissue.

        -  To evaluate the effectiveness of combination therapy using CBT-1(Registered Trademark)
           and paclitaxel in treating solid tumors and to determine whether the two drugs together
           are more effective than paclitaxel alone.

      Eligibility:

      -Patients over 18 years of age who have a solid tumor that cannot be treated successfully
      with standard treatments.

      Design:

      -Patients receive CBT-1(Registered Trademark) and paclitaxel in 21-day cycles. Treatment
      continues for two cycles after all the cancer is gone, or until it is decided to surgically
      remove some or all of the remaining cancer, or until the cancer has grown to the point where
      it defined as progressive disease.

      For each cycle, patients take CBT-1(Registered Trademark) by mouth in three divided doses
      daily for 7 days. On day 6, paclitaxel is given through a vein over 3 hours.

      Blood tests are done before starting CBT-1(Registered Trademark) and repeated periodically
      throughout treatment.

      Imaging studies computed tomography or magnetic resonance imaging (CT or MRI) are done every
      two cycles. In addition, for the first cycle only, patients undergo imaging of tumors and
      normal tissue with a 99mTc-sestamibi radionuclide scan before and after administration of
      CBT-1(Registered Trademark). This scan helps show how well the P-glycoprotein pump is being
      blocked by the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      This is a pharmacodynamic study aimed at evaluating the efficacy of CBT-1(Registered
      Trademark) as a modulator of Pgp-mediated drug efflux in patient tumors and normal tissues.
      The study will build on over a decade of experience with 99mTc-sestamibi imaging and
      rhodamine accumulation and efflux in normal circulating CD56 plus cells as surrogates for Pgp
      function. CBA Research, Inc., has carried out Phase I and II testing of CBT-1(Registered
      Trademark) as a drug resistance reversal agent, but has not yet confirmed that the inhibitor
      is able to block drug efflux.

      Objectives:

      Evaluate the impact of CBT-1(Registered Trademark) on the hepatic accumulation and retention
      of 99mTc-sestamibi in patients with relapsed or refractory solid tumor malignancies.

      Evaluate the impact of CBT-1(Registered Trademark) on P-glycoprotein-mediated efflux from
      CD56 plus peripheral mononuclear cells.

      Eligibility:

      Patients over 18 years of age who have histologic confirmation of relapsed/refractory cancer,
      following at least once standard treatment regimen, for whom there is no known standard
      therapy option capable of extending life expectancy. Patients must have an Eastern
      Cooperative Oncology Group (ECOG) performance status of 2 or better, and have hematologic,
      renal, hepatic, and metabolic parameters suggestive of adequate organ function.

      Design:

      Patients will be treated according to CBA Research Phase II trial of CBT-1 and Taxol.
      Patients will begin protocol treatment with orally administered CBT-1(Registered Trademark)
      in two or three divided doses daily for 7 days. On day 6, 135 mg/m^2 paclitaxel will be
      administered by intravenous infusion over 3 hours. Prior to the initiation of
      CBT-1(Registered Trademark), and on Day 6, patients will undergo blood sampling for the
      rhodamine assay in CD56 plus circulating mononuclear cells. In addition, patients will
      undergo imaging of tumors and normal tissue with the 99mTc-sestamibi radionuclide scan. These
      two assays have shown convincing inhibition of Pgp-mediated drug efflux in past studies with
      Pgp inhibitors such as tariquidar and valspodar. Twelve patients are planned for enrollment
      to this study, which is powered to determine a difference between the control scan and the
      post-treatment scan but not to compare CBT-1(Registered Trademark) with previous inhibitors
      tested in the intramural program.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition</measure>
    <time_frame>sestamibi scanning was performed on day 0 and day 6, allowing scans to be performed pre and post CBT-1 administration</time_frame>
    <description>An area under the concentration curve (AUC) was calculated for 99mTc counts over the liver, lungs, and heart. An equation was applied to determine the increase in sestamibi in the liver: [(AUCpost - AUC baseline)/(AUC baseline)] x 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Inhibition of Rhodamine Efflux From CD56+Cells Post Treatment</measure>
    <time_frame>Rhodamine efflux was performed on blood drawn prior to CBT-1 ingestion and after 6 days of dosing.</time_frame>
    <description>Rhodamine 123 was added to whole blood obtained before and after CBT-1. The blood was incubated, layered on lymphocyte separation medium and centrifuged. Peripheral blood mononuclear cells(PBMCs)were isolated, washed and incubated in rhodamine-free medium with or without valspodar. Cells were washed and incubated in phycoerythrin-labeled anti-CD56 antibody or negative control antibody. Rhodamine 123 fluorescence was assessed in CD56+cells with or without valspodar and a 60 min efflux period,continuing the cells without or with valspodar to generate Efflux and PSC/Efflux histograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had an Overall Response</measure>
    <time_frame>Baseline to progression</time_frame>
    <description>Response is determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Complete response (CR)-disappearance of all target lesions, Partial response (PR)-at least a 30% decrease in the sum of the longest diameter(LD)of target lesions, stable disease (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
See the Protocol Link module for further details about the RECIST Criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cervical</condition>
  <condition>Ovarian</condition>
  <condition>Lung</condition>
  <condition>Breast</condition>
  <condition>Renal</condition>
  <arm_group>
    <arm_group_label>Paclitaxel and CBT-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.</description>
    <arm_group_label>Paclitaxel and CBT-1</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Onxal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-1(Registered Trademark)</intervention_name>
    <description>CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.</description>
    <arm_group_label>Paclitaxel and CBT-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tc 99m sestamibi</intervention_name>
    <description>20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.</description>
    <arm_group_label>Paclitaxel and CBT-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients must fulfill all of the following criteria to be eligible for study admission:

          1. Age greater than 18 years.

          2. Histologic or cytologic confirmation at National Cancer Institute (NCI) Laboratory of
             Pathology, of recurrent or refractory, or advanced metastatic cancer of the
             gastrointestinal tract, breast, Taxol (Trademark) naive breast cancer, small cell
             lung, ovarian, prostate, head and neck, multiple myeloma, non-small cell lung cancer,
             Taxol (Trademark) naive non-small cell lung cancer.

          3. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2.

          4. Life expectancy of 3 months or greater.

          5. Patient must have adequate hematologic, renal, hepatic, and metabolic functions as
             defined: platelet count greater than 100,000 /mL, absolute granulocyte count (AGC)
             greater than 1500/mL, serum creatinine less than 2.0 mg/dl (or if greater than 2.0, a
             measured 24 hour creatinine clearance greater than 50 mL/min), serum glutamic
             oxaloacetic transaminase (SGOT) 4 times institutional upper limit of normal, bilirubin
             2.0 mg/dl, prothrombin time (PT) less than 1.5 times institutional upper limit of
             normal, partial thromboplastin time (PTT) less than 1.5 times institutional upper
             limit of normal, calcium less than 5.3mEq/L, albumin greater than 2.0 g/dl.

          6. Electrocardiogram (EKG) showing, at most, minor abnormalities that in the judgment of
             the protocol chairman would not compromise the patient's ability to tolerate therapy.

          7. Patients must be greater than 4 weeks from prior radiation or chemotherapy; greater
             than 2 weeks from hormonal or immunotherapy; greater than 4 weeks from prior
             experimental therapy; greater than 6 weeks from mitomycin; and greater than 8 weeks
             from prior UCN01 treatment. Patients receiving dexamethasone as a pretreatment for
             anaphylactic reactions to Taxol (Trademark) or the cremophor vehicle will not be
             excluded from this study.

          8. No serious intercurrent medical illness or serious infection that requires parenteral
             antibiotics.

          9. Measurable disease by radiographic means or physical examination.

         10. Willingness to sign a written informed consent.

         11. Patients must agree to an effective method of contraception for the study (abstinence,
             hormonal or barrier method of birth control, or condom) for the study and 30 days
             after completion of protocol.

        EXCLUSION CRITERIA:

        The following patient populations are not eligible for study:

          1. Women of childbearing potential and potentially fertile men will be excluded unless
             using an effective contraception (ie. a barrier intrauterine device (IUD), birth
             control pill, or condom), during the treatment. Women who are pregnant or nursing will
             also be excluded.

          2. Patients with significant intercurrent disease.

          3. Human Immunodeficiencey virus (HIV) seropositive patients. Note: There may be an
             impact of CBT-1 on the pharmacokinetics of the drugs used in the therapy of HIV.

          4. Ongoing serious infections that require parenteral antibiotics.

          5. Patients with significant central nervous system (CNS) disease, including a history of
             seizures within the last 3 months or psychiatric history which would impair the
             ability to give informed consent or prevent compliance with protocol requirements.

          6. Patients must not be eligible for surgery, or radiotherapy that is of known benefit to
             them, in terms of extension of survival. Patients with tumors sensitive to potentially
             curative chemotherapy must have failed such chemotherapy. Patients who have received
             radiation therapy may participate in this study one week after the conclusion of
             radiation therapy provided that the lesion being irradiated is not one that is being
             used to assess the efficacy of CBT-1 plus Taxol.

          7. History of significant coronary artery disease, cardiac arrhythmias requiring
             treatment, or history of other cardiac disease that in the judgment of the
             investigators, would compromise the patient's ability to tolerate the therapy.

          8. Patients with active bleeding due to peptic ulcer disease.

          9. History of anaphylactic reactions to paclitaxel or cremophor despite adequate
             premedication.

         10. Clinically significant bleeding disorders.

         11. Patients with solid organ allografts.

         12. Patients on daily gastric acid secretion inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan S Bates, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0035.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medline Plus</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <link>
    <url>http://ctep.cancer.gov/protocolDevelopment/default.htm</url>
    <description>RECIST Criteria</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <results_first_submitted>September 20, 2011</results_first_submitted>
  <results_first_submitted_qc>January 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2012</results_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Susan Bates</investigator_full_name>
    <investigator_title>Dr. Susan Bates</investigator_title>
  </responsible_party>
  <keyword>Pgp</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Drug Resistance</keyword>
  <keyword>Sestamibi</keyword>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
          <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
          <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.79" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition</title>
        <description>An area under the concentration curve (AUC) was calculated for 99mTc counts over the liver, lungs, and heart. An equation was applied to determine the increase in sestamibi in the liver: [(AUCpost - AUC baseline)/(AUC baseline)] x 100.</description>
        <time_frame>sestamibi scanning was performed on day 0 and day 6, allowing scans to be performed pre and post CBT-1 administration</time_frame>
        <population>As planned imaging data from 10 pts were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
            <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition</title>
          <description>An area under the concentration curve (AUC) was calculated for 99mTc counts over the liver, lungs, and heart. An equation was applied to determine the increase in sestamibi in the liver: [(AUCpost - AUC baseline)/(AUC baseline)] x 100.</description>
          <population>As planned imaging data from 10 pts were analyzed.</population>
          <units>percent increase sestamibi retention</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" lower_limit="34.7" upper_limit="100.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
            <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Inhibition of Rhodamine Efflux From CD56+Cells Post Treatment</title>
        <description>Rhodamine 123 was added to whole blood obtained before and after CBT-1. The blood was incubated, layered on lymphocyte separation medium and centrifuged. Peripheral blood mononuclear cells(PBMCs)were isolated, washed and incubated in rhodamine-free medium with or without valspodar. Cells were washed and incubated in phycoerythrin-labeled anti-CD56 antibody or negative control antibody. Rhodamine 123 fluorescence was assessed in CD56+cells with or without valspodar and a 60 min efflux period,continuing the cells without or with valspodar to generate Efflux and PSC/Efflux histograms.</description>
        <time_frame>Rhodamine efflux was performed on blood drawn prior to CBT-1 ingestion and after 6 days of dosing.</time_frame>
        <population>Rhodamine 123 fluorescence was assessed in CD56+cells after a 30 min loading period with or without exogenously added valspodar and a 60 min efflux period followed, continuing the cells with or without exogenous valspodar to generate Efflux and PSC/Efflux histograms. Percent decrease in difference between these histograms is reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
            <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Inhibition of Rhodamine Efflux From CD56+Cells Post Treatment</title>
          <description>Rhodamine 123 was added to whole blood obtained before and after CBT-1. The blood was incubated, layered on lymphocyte separation medium and centrifuged. Peripheral blood mononuclear cells(PBMCs)were isolated, washed and incubated in rhodamine-free medium with or without valspodar. Cells were washed and incubated in phycoerythrin-labeled anti-CD56 antibody or negative control antibody. Rhodamine 123 fluorescence was assessed in CD56+cells with or without valspodar and a 60 min efflux period,continuing the cells without or with valspodar to generate Efflux and PSC/Efflux histograms.</description>
          <population>Rhodamine 123 fluorescence was assessed in CD56+cells after a 30 min loading period with or without exogenously added valspodar and a 60 min efflux period followed, continuing the cells with or without exogenous valspodar to generate Efflux and PSC/Efflux histograms. Percent decrease in difference between these histograms is reported.</population>
          <units>Percent inhibition of rhodamine efflux</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="51" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had an Overall Response</title>
        <description>Response is determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Complete response (CR)-disappearance of all target lesions, Partial response (PR)-at least a 30% decrease in the sum of the longest diameter(LD)of target lesions, stable disease (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
See the Protocol Link module for further details about the RECIST Criteria.</description>
        <time_frame>Baseline to progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
            <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had an Overall Response</title>
          <description>Response is determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Complete response (CR)-disappearance of all target lesions, Partial response (PR)-at least a 30% decrease in the sum of the longest diameter(LD)of target lesions, stable disease (SD) - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
See the Protocol Link module for further details about the RECIST Criteria.</description>
          <units>participants with response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paclitaxel and CBT-1 to Treat Solid Tumors</title>
          <description>Patients will be treated with oral CBT-1 at a dose of 500 mg/m^2 daily for 7 days in divided doses and repeated every 21 days for 7 days beginning with cycle 1 of each cycle provided cycles are not delayed.
Paclitaxel will be 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days provided there is no delay, and will be administered on day 6 of each cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (pneumonia)with normal absolute neutrophil count (ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other: SVC (Superior vena cava) Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>OTHER: PULMONARY STENOSIS NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, CHEST/THORAX NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLURRED VISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DISTENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE-GI, UPPER GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MUCOSITIS (CLINICAL EXAM), ORAL CAVITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, THROAT/PHARYNX/LARYNX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, ABD NOS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, RECTUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>EDEMA, H&amp;N</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>EDEMA, LIMB</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>RIGORS/CHILLS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>INFECTION, URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>OTHER: INFECTION NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OTHER: PERFORATION NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ALT/SGPT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST/SGOT</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>BICARBONATE, SERUM LOW</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>BILIRUBIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>CREATININE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>OTHER: LDH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERCALCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERURICEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINEMIA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERMAGNESEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OTHER: RUQ PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, BACK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, JOINT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, MUSCLE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PAIN, TUMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NEUROPATHY-CRANIAL: CN-V MOTOR-JAW MUSCLES; SENSORY-FACIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NEUROPATHY-SENSORY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PAIN, HEAD/HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION-ANXIETY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION, DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMOGLOBINURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>OTHER: DYSURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>VOICE CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PRURITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>OTHER: LYMPHEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan S. Bates, M.D.</name_or_title>
      <organization>National Cancer Institute (NCI), National Institutes of Health (NIH)</organization>
      <phone>301-402-0984</phone>
      <email>Batess@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

